Isomorphic collaborates with Lilly to discover therapeutics against multiple targets; Eli Lilly launches LillyDirect for obesity, migraine and diabetic patients

Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, announced that it has entered into a strategic research collaboration with Eli Lilly, an American pharma company headquartered in Indianapolis unites caring with discovery to create medicines that make life better for people around the world. This marks Isomorphic Labs’ first pharmaceutical partnership with Eli Lilly.

Under the terms of the agreement, Isomorphic Labs will partner with Lilly to discover small molecule therapeutics against multiple targets and will receive an upfront cash payment of $45 million. Isomorphic Labs is eligible to receive up to $1.7 billion in performance-based milestone payments, excluding the upfront payment and any subsequent tiered royalties of up to low double digits on net sales.

"We're thrilled to embark on this partnership and apply our proprietary technology platform, the next generation of AlphaFold, and access to massive computing power to Lilly's development programs," said Demis Hassabis, CEO and founder of Isomorphic Labs. "The focus we share on advancing groundbreaking drug design approaches and appreciation of state-of-the-art science makes this partnership particularly compelling."

Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of artificial intelligence to drug discovery. The company is reimagining the entire drug discovery process from first principles with an artificial intelligence-first approach, working to build powerful new predictive and generative models of biological phenomena to anticipate how drugs will perform and design novel molecules.

Last week Eli Lilly has launched ‘LillyDirect’, a new digital healthcare experience for patients in the US living with obesity, migraine and diabetes. It offers disease management resources, including access to independent healthcare providers, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services. With LillyDirect, company’s goal is to relieve some of those burdens by simplifying the patient experience to help improve outcomes

LillyDirect offers: LillyDirect pharmacy solutions, a digital pharmacy for select Lilly medicines powered by third party online pharmacy fulfillment services. LillyDirect pharmacy solutions gives patients a simple option to get consistent access to Lilly medicines they have been prescribed with the added convenience of home delivery. By obtaining medicines directly from Lilly, patients can easily access Lilly's affordability solutions and savings card opportunities are automatically applied for patients who qualify. Medicines fulfilled by pharmacy service providers through LillyDirect Pharmacy Solutions ship free of charge.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!